
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics Inc exhibits a promising outlook due to the increasing revenue projections for its lead asset, zorevunersen, with expectations of launch in FY28 and potential revenue targets raised to $32, reflecting growing confidence in its market entry. The company's Phase I/II study data indicates robust seizure reduction of approximately 82% and meaningful cognitive benefits, which not only strengthens the case for zorevunersen as a viable treatment for Dravet syndrome but also de-risks the upcoming Phase 3 EMPEROR study. Furthermore, the possibility of expedited FDA approval could elevate revenue expectations even further, potentially pushing targets into the low-$40s, underscoring the strong market potential for Stoke Therapeutics's pipeline.
Bears say
Stoke Therapeutics has experienced a significant decline in share price, dropping 15% in reaction to market events affecting a related company, indicating heightened volatility and investor concern. The company's future valuation is at risk, contingent upon the issuance and protection of key patents, as any disputes or failures in securing these patents could negatively impact market success and financial projections. Additionally, the company faces stiff competition in the Dravet market, where existing therapies have captured over 20% market share, raising questions about the potential adoption and long-term benefits of its lead product, zorevunersen.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares